TRT And Bone Density: How Testosterone Affects Your Bones

Testosterone replacement therapy has been shown to increase bone mineral density in men with diagnosed hypogonadism, but that increase doesn't automatically lower fracture risk. The relationship between TRT and bone density is more complicated than earlier research suggested, and the most recent large-scale trial data have changed how clinicians weigh the benefits.

Marek Health provides lab-based evaluations for men concerned about hormone-related bone health. Understanding what the current evidence shows and where gaps remain matters before starting or continuing therapy.

TRT and bone density describes the effect of testosterone replacement therapy on bone mineral density (BMD) in men with low testosterone confirmed by lab testing. Multiple trials show BMD gains, with the largest effects in trabecular bone, but fracture reduction has not been demonstrated in randomized controlled data.

How Does Testosterone Affect Bone Remodeling?

Bone constantly breaks down and rebuilds through remodeling. Two cell types drive this: osteoblasts form new bone, and osteoclasts resorb old bone. Testosterone influences both.

Androgen receptors on osteoblasts and osteocytes support new bone formation and periosteal expansion (Tenuta et al., 2025). Testosterone also converts to estradiol through aromatase activity, and estradiol plays a separate role in suppressing bone resorption. The direct androgenic effects appear strongest on cortical bone (the dense outer shell), while the indirect estradiol-mediated effects have greater influence on trabecular bone (the spongy interior in the spine and pelvis).

What Do Clinical Trials Show About TRT and Bone Density?

The TTrials Bone Trial found that one year of testosterone gel increased volumetric trabecular BMD at the spine and estimated bone strength in men 65 and older with low testosterone (Snyder et al., 2017). The Endocrine Society's 2018 guideline acknowledged these BMD gains but noted that no studies had demonstrated fracture risk reduction with TRT alone (Bhasin et al., 2018).

The TRAVERSE fracture substudy changed that picture. It enrolled 5,204 hypogonadal men and followed them for a median of 3.19 years. Fractures occurred in 3.50% of the testosterone group versus 2.46% of placebo (HR 1.43, 95% CI 1.04-1.97) (Snyder et al., 2024). The main TRAVERSE cardiovascular trial also reported higher incidence of atrial fibrillation and pulmonary embolism in the testosterone arm, with a neutral primary cardiovascular endpoint (MACE): 7.0% versus 7.3% (Lincoff et al., 2023). Based on TRAVERSE, the FDA removed the cardiovascular boxed warning from testosterone products in February 2025 but added a blood pressure warning (FDA, 2025).

BMD increased with TRT in trial data, but the TRAVERSE fracture substudy did not demonstrate a reduction in clinical fractures. Possible explanations include fall risk factors unrelated to bone density and the fact that BMD alone doesn't capture all contributors to fracture risk.

How Is Bone Density Measured?

Dual-energy x-ray absorptiometry (DXA) is the standard test. It produces a T-score comparing BMD to the average of healthy young adults. The WHO defines osteoporosis as a T-score 2.5 or more standard deviations below the young adult average. Each standard deviation below normal is associated with approximately double the fracture risk, according to WHO fracture risk models.

The AUA's 2018 guideline recommends measuring total testosterone in men with unexplained bone density loss (AUA, 2018), and the Endocrine Society recommends repeating DXA after 1-2 years of TRT in hypogonadal men with osteoporosis (Bhasin et al., 2018). Quantitative computed tomography (QCT) offers a more detailed view by separately measuring trabecular and cortical compartments.

Is Osteoporosis Underdiagnosed in Men?

Hypogonadism accounts for 16-30% of male osteoporosis cases, and men with low testosterone have a fracture odds ratio of 1.76 (95% CI, 1.37-2.26) compared to eugonadal men (Tenuta et al., 2025). Hip fractures in men are associated with higher mortality rates than in women. Vertebral fractures often go undetected until imaging reveals height loss.

The Endocrine Society recommends screening hypogonadal men for bone health and testing men with osteoporosis for testosterone deficiency (Bhasin et al., 2018). Guidelines generally require two separate early-morning total testosterone draws below established thresholds (the AUA uses 300 ng/dL) plus clinical symptoms.

Should TRT Be the Only Treatment for Bone Loss?

No. Antiresorptive therapies (bisphosphonates, denosumab) remain first-line for male osteoporosis, even when hypogonadism is present. TRT may complement those medications when a man also has diagnosed testosterone deficiency, but it doesn't substitute for established fracture-prevention therapy. Research into combined protocols remains limited.

Lifestyle factors also matter for bone health. Weight-bearing and resistance exercise are associated with bone formation and are commonly recommended for bone health. Adequate calcium and vitamin D intake are generally recommended to support bone mineralization. Smoking cessation reduces a known risk factor for accelerated bone loss.

What Should Men Consider Before Starting TRT for Bone Health?

TRT addresses a diagnosed hormonal deficiency. It doesn't bypass the diagnostic process: two early-morning labs confirming total testosterone below 300 ng/dL, clinical symptoms, and evaluation by a licensed clinician. A prescription is issued only when medically appropriate.

BMD improvements are well-documented, but fracture reduction hasn't been proven in randomized data. Monitoring on TRT includes periodic lab work for hematocrit, PSA, estradiol, and blood pressure, plus DXA follow-up for those with baseline osteoporosis. The TRAVERSE secondary signals reinforce that TRT requires ongoing clinical oversight. Fertility suppression is another consideration; this effect is variable and not guaranteed to reverse after discontinuation.

A full hormone panel and metabolic workup provide context that a single testosterone value can't. TRT and bone density are connected, but the decision to treat involves the full clinical picture.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

Does TRT improve bone density in men with low testosterone?

Yes. The TTrials Bone Trial showed that one year of testosterone treatment increased volumetric trabecular BMD at the spine and estimated bone strength in men 65 and older with confirmed low testosterone. The Endocrine Society's 2018 guideline also recognizes BMD gains with TRT in hypogonadal men. These increases are most pronounced in trabecular bone.

Does TRT reduce fracture risk?

Current evidence says no. The TRAVERSE fracture substudy followed 5,204 hypogonadal men for a median of 3.19 years and found that testosterone did not lower clinical fracture incidence. Fractures occurred in 3.50% of the testosterone group versus 2.46% of the placebo group (HR 1.43, 95% CI 1.04-1.97).

How is bone density tested?

DXA (dual-energy x-ray absorptiometry) is the standard test. It produces a T-score comparing BMD to healthy young adults. The WHO classifies a T-score of -2.5 or below as osteoporosis. QCT (quantitative computed tomography) provides a more detailed look by separately measuring trabecular and cortical bone.

Can TRT replace osteoporosis medications?

No. The Endocrine Society states that antiresorptive therapies (bisphosphonates, denosumab) remain the primary treatment for male osteoporosis. TRT may complement these medications when a man also has diagnosed testosterone deficiency, but it doesn't substitute for established fracture-prevention therapy.

What monitoring is needed for TRT and bone density?

The Endocrine Society recommends repeating DXA after 1-2 years in hypogonadal men with osteoporosis who are receiving TRT. Routine TRT monitoring also includes hematocrit, PSA, estradiol, and blood pressure. The AUA recommends checking total testosterone in any man with unexplained bone density loss.

Is osteoporosis common in men with low testosterone?

Hypogonadism accounts for 16-30% of male osteoporosis cases. Men with low testosterone have a fracture odds ratio of 1.76 compared to men with normal levels. Hip fractures in men are also associated with higher mortality rates than in women, making early detection through lab work and DXA scanning clinically relevant.

References

• Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117

• Effect of Testosterone Treatment on Volumetric Bone Density and Strength in Older Men With Low Testosterone. JAMA Intern Med. 2017;177(4):471-479

• Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432

• FDA Issues Class-Wide Labeling Changes for Testosterone Products. Feb 2025

• Testosterone and Male Bone Health: A Puzzle of Interactions. J Clin Endocrinol Metab. 2025;110(7):e2121-e2135

• Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744

• Testosterone Treatment and Fractures in Men with Hypogonadism. N Engl J Med. 2024;390(3):203-211